Dextropropoxyphene (International)
Scheme
Prop.INN
ATC (Anatomical Therapeutic Chemical Classification)
N02AC04
CAS registry number (Chemical Abstracts Service)
0000469-62-5
Chemical Formula
C22-H29-N-O2
Molecular Weight
339
Therapeutic Categories
Opioid analgesic
Opioid receptor agonist
Chemical Names
(1S,2R)-1-Benzyl-3-dimetylamino-2-metyl-1-phenylpropyl propionate (BAN)
4-Dimetylamino-1,2-diphenyl-3-metyl-2-propionoxybutane (WHO)
Foreign Names
- Dextropropoxyphenum (Latin)
- Dextropropoxyphen (German)
- Dextropropoxyphène (French)
- Dextropropoxifeno (Spanish)
Generic Names
- Destropropoxifene (OS: DCIT)
- Dextropropoxyphene (OS: BAN)
- Propoxyphène (OS: DCF)
- L 16298 (IS)
- α-$Id$R-propoxyphene (IS)
- UNII-S2F83W92TK (IS)
- Dextropropoxyphene Hydrochloride (OS: BANM)
- Propoxyphene Hydrochloride (OS: USAN)
- SK 65 (IS)
- UNII-CB2TL9PS0T (IS)
- Dextropropoxyphène (chlorhydrate de) (PH: Ph. Eur. 9)
- Dextropropoxyphene Hydrochloride (PH: BP 2018)
- Dextropropoxyphene hydrochloride (PH: Ph. Eur. 9)
- Dextropropoxyphenhydrochlorid (PH: Ph. Eur. 9)
- Dextropropoxypheni hydrochloridum (PH: Ph. Eur. 9)
- Propoxyphene Hydrochloride (PH: USP 35)
- Dextropropoxyphene Napsilate (OS: BANM)
- Propoxyphene Napsylate (OS: USAN)
- Dextropropoxyphene 2-naphtalenesulfonate (IS)
- Dextropropoxyphene Napsylate (IS)
- S-9700 (IS)
- UNII-38M219L1OJ (IS)
- Dextropropoxyphene Napsilate (PH: BP 2018)
- Propoxyphene Napsylate (PH: USP 35)
Brand Names
- Acrogesico
Acromax, Ecuador - Algaphan [+ Paracetamol]
Efroze, Pakistan - Darvocet [+ Paracetamol]
Ranbaxy, India - Dextrodip [+ Metamizole]
Drawer, Argentina - Dianagesic [+ Paracetamol]
Helicon, Pakistan - Dibagesic
Diba, Mexico - Distalgesic [+ Paracetamol]
Dista, Egypt - Femldol [+ Chlorpheniramine]
Pacific, Pakistan - Klosidol [+ Metamizole]
Bago, Argentina - Lafegesic [+ Ibuprofen]
Lafedar, Argentina - Lupivon [+ Paracetamol]
Lupin, India - Sudhinol [+ Paracetamol]
Ranbaxy, India - Algaphan [+ Paracetamol]
Efroze, Kenya - Analphene [+ Paracetamol]
Lisko, Pakistan - Corbutyl [+ Paracetamol]
Sanofi Aventis, India - Dacoton
Standard, Taiwan - Darvin [+ Paracetamol]
Pharmedic, Pakistan - Darwocit [+ Paracetamol]
Wilshire, Pakistan - Depain X [+Paracetamol]
Panion & BF, Taiwan - Deprogesic [+ Paracetamol]
Popular, Pakistan - Dextasgesic [+ Paracetamol]
Eros, Pakistan - Diagesic [+ Paracetamol]
Wilshire, Pakistan - Dipirona + Dextropropoxifeno Larjan [+ Metamizole]
Larjan, Uruguay - Distalgesic [+ Paracetamol]
Eli Lilly, Pakistan - Dolpocetmol [+ Paracetamol]
Synco, Hong Kong - Draphene [+ Paracetamol]
Lisko, Pakistan - Dypon [+ Paracetamol]
Donvalley, Pakistan - Jalgesic [+ Paracetamol]
Irza, Pakistan - Medonol [+ Paracetamol]
Medochemie, Hong Kong - Neo-Percodan [+ Paracetamol]
Sanofi-Aventis, Mexico - Panat [+ Metamizole]
FU, Uruguay - Propoxyphene Hydrochlorie NBCD
NBCD/ DOH, Taiwan - Proxyvon [+ Paracetamol]
Wockhardt, India - Qual [+ Paracetamol, + Diazepam]
Silanes, Mexico - Romidon
Stragen Nordic, Greece - Saludex
Salus, Mexico - Tong-Well [+ Paracetamol]
Royal, Taiwan - U-comphen [+ Paracetamol]
U-Liang, Taiwan - Wygesic [+ Paracetamol]
Wyeth, India - Da Ning [+ Paracetamol]
HengRui Medicine, China - Klosidol [+ Metamizole]
Bago, Paraguay; Bagó, Ecuador - Lifron [+ Metamizol]
Life, Ecuador - Proxyvon [+ Paracetamol]
Wockhardt, India - Spasmo-Proxyvon [+ Dicycloverine, + Paracetamol]
Wockhardt, India - Tong Li Tuo [+ Paracetamol]
Shenyang First Pharmaceutical Factory, China - Vicefeno [+ Metamizole]
Fabra, Argentina
Glossary
Term | Definition |
---|---|
BAN | British Approved Name |
BANM | British Approved Name (Modified) |
DCF | Dénomination Commune Française |
DCIT | Denominazione Comune Italiana |
IS | Inofficial Synonym |
OS | Official Synonym |
PH | Pharmacopoeia Name |
Prop.INN | Proposed International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
WHO | World Health Organization |
Further information on drug naming conventions: International Nonproprietary Names.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.